Navigation Links
Sentillion Introduces Affordable Next Generation Healthcare Single Sign-On Solution Called expreSSO(TM)
Date:9/10/2007

,

-- Disaster recovery-ready for multi-site active or hot-standby

deployment,

-- Centralized single sign-on audit log with built-in reporting,

-- And an array of fixed-fee services and support options to meet the

specific needs of each organization.

For almost a decade, Sentillion has been at the forefront of innovation when it comes to delivering solutions that help healthcare organizations overcome the challenges associated with identity and access management. The first company to bring an SSO solution on a network appliance to market, Sentillion's IAM solutions are the most widely deployed in healthcare and used daily by more than 275,000 caregivers.

"With our unwavering commitment to bringing our customers live, Sentillion has clearly established itself as the lowest risk, highest value option among all identity and access management offerings," said Robert Seliger, Sentillion's CEO. "Now, with expreSSO we are delighted to make the core benefits of our technology even more appealing by offering healthcare organizations a new option: an affordable SSO solution that quickly and easily improves caregiver satisfaction and provides an immediate return on investment."

Pricing & Availability

For pricing details, please contact Sentillion directly. The product will be generally available in Q4 2007.

For More Information

To learn more about expreSSO, please visit http://www.sentillion.com/expresso.

About Sentillion

Since 1998, Sentillion has been revolutionizing healthcare IT with award winning, industry recognized identity and access management technology. Sentillion has successfully combined patented technology with a deep understanding of the healthcare industry to deliver the most comprehensive set of solutions for single sign-on, user provisioning, clinical workstations and virtualized remote access. Sentillion is the onl
'/>"/>

SOURCE Sentillion, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. E Merck introduces Livogen Z with zinc sulphate
2. TI Cycles Introduces Foldman
3. Canada Introduces Mandatory Nutrition Labeling
4. Amgen introduces Autoinjector For Treating Anemia
5. Cuba Introduces New Device for Detecting Vascular Diseases
6. China Introduces Solar-powered Baths
7. Allergan Introduces ‘Dermal Filler’ for Smile Lins
8. UAE Introduces Cervical Cancer Vaccine
9. Cynosure Introduces Higher Power Smartlipo(TM) LaserBodySculpting Workstation
10. Iceland Introduces Smoking Ban in Bars and Restaurants
11. Indian Introduces Paan-flavoured Condoms
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 2AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 3China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3Haemonetics Sets Date for First Quarter Fiscal Year 2010 Earnings Release 3A August 3 2009 51439 1Varian Medical Systems Management to Present at the Piper Jaffray Cancer Summit 51436 1Medical Imaging Modality Vendors Should Focus on Innovation and Alliances with Market Leaders Advises Frost 26 Sullivan 51431 1Medical Imaging Modality Vendors Should Focus on Innovation and Alliances with Market Leaders Advises Frost 26 Sullivan 51431 2Medical Imaging Modality Vendors Should Focus on Innovation and Alliances with Market Leaders Advises Frost 26 Sullivan 51431 3